Cefodizime in acute purulent exacerbations of chronic respiratory disease.
Clinical, microbiological and pharmacokinetic studies were carried out after 1 or 2 g intramuscular injections bd of cefodizime (HR 221), a new aminothiazolyl cephalosporin, in 41 patients hospitalized for acute purulent exacerbations of chronic respiratory disease. Treatment was for 10 days. Serum Cmax values of 54.8 and 84.7 mg/l were recorded approximately 2 hours after the injections, the corresponding sputum values averaging 1.01 and 2.58 mg/l. Penetration from blood to sputum was 2 to 3.6%. The elimination phase half-life in serum was approximately 4.5 h. Clinical, microbiological and pharmacokinetic studies were carried out after 1 or 2 g intramuscular injections bd of cefodizime (HR 221), a new aminothiazolyl cephalosporin, in 41 patients hospitalized for acute purulent exacerbations of chronic respirators disease. Treatment was for 10 days. Serum Cmax values of 54.8 and 84.7 mg/l were recorded approximately 2 hours after the injections, the corresponding sputum values averaging 1.01 and 2.58 mg/l. Penetration from blood to sputum was 2 to 3.6%. The elimination phase half-life in serum was approximately 4.5 h.
Maesen
F P
FP
Department of Respiratory Diseases, De Wever Ziekenhuis, Heerlen, The Netherlands.
Davies
B I
BI
Baur
C
C
Sumajow
C A
CA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D013492:Suppuration
D002439:Cefotaxime; C033356:cefodizime